AU1462300A - Human pan-hcv human monoclonal antibodies - Google Patents

Human pan-hcv human monoclonal antibodies

Info

Publication number
AU1462300A
AU1462300A AU14623/00A AU1462300A AU1462300A AU 1462300 A AU1462300 A AU 1462300A AU 14623/00 A AU14623/00 A AU 14623/00A AU 1462300 A AU1462300 A AU 1462300A AU 1462300 A AU1462300 A AU 1462300A
Authority
AU
Australia
Prior art keywords
human
monoclonal antibodies
hcv
pan
human monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14623/00A
Other languages
English (en)
Inventor
Steven K.H. Foung
Kenneth G Hadlock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU1462300A publication Critical patent/AU1462300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU14623/00A 1998-11-05 1999-10-29 Human pan-hcv human monoclonal antibodies Abandoned AU1462300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18705798A 1998-11-05 1998-11-05
US09187057 1998-11-05
PCT/US1999/025711 WO2000026418A1 (en) 1998-11-05 1999-10-29 Human pan-hcv human monoclonal antibodies

Publications (1)

Publication Number Publication Date
AU1462300A true AU1462300A (en) 2000-05-22

Family

ID=22687437

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14623/00A Abandoned AU1462300A (en) 1998-11-05 1999-10-29 Human pan-hcv human monoclonal antibodies

Country Status (5)

Country Link
US (1) US6692908B1 (enExample)
EP (1) EP1127170A4 (enExample)
JP (1) JP2002528140A (enExample)
AU (1) AU1462300A (enExample)
WO (1) WO2000026418A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4593783B2 (ja) * 1998-07-21 2010-12-08 ゲンマブ・アクティーゼルスカブ 抗ｃ型肝炎ウイルス抗体およびその使用
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
US20060188511A1 (en) * 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
WO2000026418A1 (en) 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
US7084266B1 (en) 1999-06-04 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cloned genome of infectious hepatitus C virus of genotype 2A and uses thereof
WO2000075338A2 (en) * 1999-06-04 2000-12-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services CLONED GENONE OF INFECTIOUS HEPATITIS C VIRUS OF GENOTYPE 2a AND USES THEREOF
EP1245236A4 (en) * 1999-12-28 2004-09-22 Sumitomo Pharma PROPHYLACTICS AND THERAPEUTICS FOR TREATING CHRONIC HEPATITIS
WO2001058459A1 (fr) * 2000-02-14 2001-08-16 Mitsubishi Pharma Corporation Remedes contre l'hepatite c
IL137522A (en) * 2000-07-26 2007-06-17 Drk Blutspendediendst Baden Wu Human monoclonal antibody against hepatitis c virus e2 glycoprotein
JP2004524829A (ja) * 2000-12-01 2004-08-19 アメリカ合衆国 Ｃ型肝炎ウイルスのｅ２糖タンパク質に特異的なモノクローナル抗体、ならびにｃ型肝炎の診断、治療、および予防におけるそれらの使用
ATE425187T1 (de) 2001-01-12 2009-03-15 Molecules Of Man Ab Materialien und methoden zur behandlung von hepatitis c
US7374876B2 (en) * 2001-04-03 2008-05-20 Rapid Medical Diagnostic Corporation Anti-idiotypic antibody and its use in diagnosis and therapy of Hepatitis C Virus related diseases
EP1379690A4 (en) * 2001-04-12 2004-08-18 Biocore Co Ltd OLIGONUCLEOTIDE CHIP COMPOSITION FOR THE ANALYSIS OF THE HEPATITIS C VIRUS GENOTYPE (HCV), AND DETECTION METHOD THEREOF
EP1456668B1 (en) * 2001-12-05 2007-05-02 Sense Proteomic Limited Protein arrays for allelic variants and uses thereof
AU2003243316A1 (en) 2002-05-24 2003-12-12 Nps Allelix Corp. Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
EP1521767B1 (en) * 2002-05-24 2009-12-16 Restoragen Inc. Methods and constructs for high yield expression of clostripain
US7829307B2 (en) 2003-11-21 2010-11-09 Nps Pharmaceuticals, Inc. Production of glucagon-like peptide 2
WO2006028634A2 (en) * 2004-09-01 2006-03-16 Vijay Ramakrishnan Site specific pegylation of broadly-neutralizing antibodies against hepatitis c virus and their use in the treatment of chronic hcv infections
US7592315B2 (en) 2004-11-02 2009-09-22 Schering Corporation Peptide viral entry inhibitors
WO2006129786A1 (ja) * 2005-06-02 2006-12-07 Akira Matsumori C型肝炎ウイルス感染の診断、予防および治療方法
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
EP2061805B1 (en) 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Recombinant hcv e2 glycoprotein
RS53258B (sr) * 2007-02-21 2014-08-29 University Of Massachusetts Humana antitela protiv virusa hepatitisa c (hcv) i njihove upotrebe
DK2862876T3 (en) 2008-09-30 2016-05-23 Toray Industries Antibody binding to envelope protein 2 of hepatitis C virus and method for identifying the genotype of hepatitis C virus using the same
CA2738644A1 (en) * 2008-10-05 2010-05-08 The Board Of Trustees Of The Leland Stanford Junior University Hepatitis c antibodies and uses thereof
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
WO2011034660A1 (en) 2009-09-16 2011-03-24 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
IN2012DN03354A (enExample) 2009-12-02 2015-10-23 Immunomedics Inc
CA2800734A1 (en) * 2010-05-25 2011-12-01 Universite De Strasbourg Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
ES2978993T3 (es) 2014-02-21 2024-09-23 Ibc Pharmaceuticals Inc Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
PL3204018T3 (pl) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
CA3178687A1 (en) * 2020-04-12 2021-10-21 Aethlon Medical, Inc. Devices and methods for treating a coronavirus infection and symptoms thereof
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
JPH07299655A (ja) 1994-04-30 1995-11-14 Aisin Seiki Co Ltd 内スプライン歯面仕上機
US6747136B2 (en) * 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
US6538114B1 (en) * 1996-04-19 2003-03-25 Karolina Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
CA2305715A1 (en) 1997-11-06 1999-05-20 Innogenetics N.V. Host derived proteins binding hcv: medical, diagnostic and purification use
WO2000026418A1 (en) 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies

Also Published As

Publication number Publication date
JP2002528140A (ja) 2002-09-03
EP1127170A1 (en) 2001-08-29
EP1127170A4 (en) 2005-04-27
WO2000026418A1 (en) 2000-05-11
US6692908B1 (en) 2004-02-17

Similar Documents

Publication Publication Date Title
AU1704099A (en) Monoclonal human natural antibodies
AU1550300A (en) Antigen-binding proteins
AU4042195A (en) Anti-alphaV-integrin monoclonal antibody
IL128406A0 (en) Monoclonal antibodies
GB9809839D0 (en) Antibody
AU3811495A (en) Antibodies
AU1290001A (en) Antibodies
HUP0104604A3 (en) Human monoclonal antibodies to ctla-4
GB9603256D0 (en) Antibodies
EP1073464A4 (en) MONOCLONAL ANTIBODIES WITH REDUCED IMMUNIZABILITY
PL330111A1 (en) Concentyratyed antibody preparation
AU4935000A (en) Antibodies
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
AU5441000A (en) Human monoclonal antibody
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
AU7072998A (en) Immunoassays using anti-allotypic monoclonal antibodies
HUP9800613A3 (en) Humanized antibody against human fas-antigene
AU5970198A (en) Anti-fas antibodies
AU3253699A (en) Myxochelines
GB9718911D0 (en) Monoclonal antibodies
AU2452301A (en) Protein methylarginine-specific antibodies
GB9818915D0 (en) Antibodies
GB9828700D0 (en) Antibody
AU5046700A (en) Diagnostic monoclonal antibody for LTiGTyersinia pestisLT/iGT

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase